New mRNA flu shot passes first safety test in humans
NCT ID NCT05446740
First seen Mar 12, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This early-stage study tested a new mRNA-based flu vaccine from GSK in 324 healthy younger (18-45) and older (60-80) adults. The main goal was to see if the vaccine is safe and triggers an immune response. Researchers monitored side effects like pain, fever, and fatigue, and measured antibody levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Halifax, Nova Scotia, B3J 3G9, Canada
-
GSK Investigational Site
Sherbrooke, Quebec, J1L 0H8, Canada
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
Conditions
Explore the condition pages connected to this study.